[go: up one dir, main page]

SE0300831D0 - New formulations and use therof - Google Patents

New formulations and use therof

Info

Publication number
SE0300831D0
SE0300831D0 SE0300831A SE0300831A SE0300831D0 SE 0300831 D0 SE0300831 D0 SE 0300831D0 SE 0300831 A SE0300831 A SE 0300831A SE 0300831 A SE0300831 A SE 0300831A SE 0300831 D0 SE0300831 D0 SE 0300831D0
Authority
SE
Sweden
Prior art keywords
new formulations
use therof
formulation
therof
apis
Prior art date
Application number
SE0300831A
Other languages
Swedish (sv)
Inventor
Fredrik Nicklasson
Kristina Thyresson
Nils-Olof Lindberg
Alice C Martino
Kristina Lindell
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Priority to SE0300831A priority Critical patent/SE0300831D0/en
Publication of SE0300831D0 publication Critical patent/SE0300831D0/en
Priority to JP2006506377A priority patent/JP2006521348A/en
Priority to AU2004224557A priority patent/AU2004224557B2/en
Priority to EP04720946A priority patent/EP1605921A1/en
Priority to MXPA05010196A priority patent/MXPA05010196A/en
Priority to CA002519155A priority patent/CA2519155A1/en
Priority to BRPI0408655-4A priority patent/BRPI0408655A/en
Priority to CNA2004800077898A priority patent/CN1764440A/en
Priority to PCT/IB2004/000860 priority patent/WO2004084865A1/en
Priority to CL200400564A priority patent/CL2004000564A1/en
Priority to TW093107802A priority patent/TW200503782A/en
Priority to ARP040100981A priority patent/AR043772A1/en
Priority to US10/816,672 priority patent/US20040191298A1/en
Priority to ZA200507719A priority patent/ZA200507719B/en
Priority to US12/143,001 priority patent/US20080249143A1/en
Priority to US12/709,953 priority patent/US20100197742A1/en
Priority to JP2010255113A priority patent/JP2011079841A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Alternative & Traditional Medicine (AREA)

Abstract

A pharmaceutical formulation comprising one or more active pharmaceutical ingredients (APIs) suitable for intraoral uptake, that comprises cocoa powder, a process for manufacturing the formulation and use of the formulation for medical treatment.
SE0300831A 2003-03-26 2003-03-26 New formulations and use therof SE0300831D0 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
SE0300831A SE0300831D0 (en) 2003-03-26 2003-03-26 New formulations and use therof
AU2004224557A AU2004224557B2 (en) 2003-03-26 2004-03-16 Formulations comprising an active ingredient and cocoa powder and use thereof
BRPI0408655-4A BRPI0408655A (en) 2003-03-26 2004-03-16 formulations comprising an active agent and cocoa powder and their use
PCT/IB2004/000860 WO2004084865A1 (en) 2003-03-26 2004-03-16 Formulations comprising an active ingredient and cocoa powder and use thereof
EP04720946A EP1605921A1 (en) 2003-03-26 2004-03-16 Formulations comprising an active ingredient and cocoa powder and use thereof
MXPA05010196A MXPA05010196A (en) 2003-03-26 2004-03-16 Formulations comprising an active ingredient and cocoa powder and use thereof.
CA002519155A CA2519155A1 (en) 2003-03-26 2004-03-16 Formulations comprising an active ingredient and cocoa powder and use thereof
JP2006506377A JP2006521348A (en) 2003-03-26 2004-03-16 Formulation containing active ingredient and cacao powder and use thereof
CNA2004800077898A CN1764440A (en) 2003-03-26 2004-03-16 Formulations comprising an active ingredient and cocoa powder and use thereof
CL200400564A CL2004000564A1 (en) 2003-03-26 2004-03-18 PHARMACEUTICAL FORMULATION FOR ORAL ADMINISTRATION THAT INCLUDES ONE OR MORE PHARMACEUTICALLY ACTIVE AGENTS AND COCOA POWDER.
TW093107802A TW200503782A (en) 2003-03-26 2004-03-23 New formulations and use thereof
ARP040100981A AR043772A1 (en) 2003-03-26 2004-03-24 FORMULATIONS THAT INCLUDE AN ACTIVE INGREDIENT AND COCOA POWDER AND ITS USE
US10/816,672 US20040191298A1 (en) 2003-03-26 2004-04-02 New formulations and use thereof
ZA200507719A ZA200507719B (en) 2003-03-26 2005-09-23 Formulations comprising an active ingredient and cocoa powder and use thereof
US12/143,001 US20080249143A1 (en) 2003-03-26 2008-06-20 New formulations and use thereof
US12/709,953 US20100197742A1 (en) 2003-03-26 2010-02-22 New formulations and use thereof
JP2010255113A JP2011079841A (en) 2003-03-26 2010-11-15 Formulation containing active ingredient and cacao powder, and use thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0300831A SE0300831D0 (en) 2003-03-26 2003-03-26 New formulations and use therof

Publications (1)

Publication Number Publication Date
SE0300831D0 true SE0300831D0 (en) 2003-03-26

Family

ID=20290786

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0300831A SE0300831D0 (en) 2003-03-26 2003-03-26 New formulations and use therof

Country Status (13)

Country Link
EP (1) EP1605921A1 (en)
JP (2) JP2006521348A (en)
CN (1) CN1764440A (en)
AR (1) AR043772A1 (en)
AU (1) AU2004224557B2 (en)
BR (1) BRPI0408655A (en)
CA (1) CA2519155A1 (en)
CL (1) CL2004000564A1 (en)
MX (1) MXPA05010196A (en)
SE (1) SE0300831D0 (en)
TW (1) TW200503782A (en)
WO (1) WO2004084865A1 (en)
ZA (1) ZA200507719B (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
ES2374717T3 (en) 1999-10-29 2012-02-21 Euro-Celtique S.A. FORMULATIONS OF CONTROLLED RELEASE HYDROCODONE.
KR100968128B1 (en) 2000-10-30 2010-07-06 유로-셀티크 소시에떼 아노뉨 Sustained Release Hydrocodone Formulations
CN101237850A (en) * 2005-08-02 2008-08-06 德罗萨帕尔姆股份公司 Pharmaceutical composition containing indometacin and/or acemetacin
US20080069891A1 (en) 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
KR101567105B1 (en) 2007-06-13 2015-11-06 오츠카 세이야쿠 가부시키가이샤 Equol-containing extract, method for production thereof, method for extraction of equol
CN101444273B (en) * 2007-11-22 2013-04-24 何煜 Health product oral fast-release preparation and production method thereof
CN101439053A (en) * 2007-11-22 2009-05-27 何煜 Chinese medicine rapid-release preparation for oral cavity and method for producing the same
WO2009070978A1 (en) * 2007-11-22 2009-06-11 Yu He An oral cavity rapid release of the health products and its preparation method
MX2011012078A (en) * 2009-05-20 2012-03-14 Lingual Consegna Pty Ltd Buccal and/or sublingual therapeutic formulation.
US8263581B2 (en) 2009-07-03 2012-09-11 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
US8513259B2 (en) 2009-07-03 2013-08-20 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
WO2011143120A1 (en) 2010-05-11 2011-11-17 Cima Labs Inc. Alcoholres i stant metoprolol - containing extended - release oral dosage forms
EP2964243B1 (en) 2013-03-06 2022-11-23 Capsugel Belgium NV Curcumin solid lipid particles and methods for their preparation and use
CN103583781B (en) * 2013-11-01 2015-11-25 阳波 Caf metronidazole chewing gum
US20170112762A1 (en) * 2014-06-10 2017-04-27 Capsugel Belgium Nv Orally disintegrating tablet containing solid lipid particles and methods for their preparation and use
US11324699B2 (en) 2014-12-04 2022-05-10 Capsugel Belgium Nv Lipid multiparticulate formulations
JP6334482B2 (en) * 2015-08-28 2018-05-30 中野Ｂｃ株式会社 Solid agent and production method thereof
WO2017100062A1 (en) * 2015-12-09 2017-06-15 Poviva Tea, Llc Methods for formulating orally ingestible compositions comprising lipophilic active agents
CN108430233A (en) * 2015-12-09 2018-08-21 波维瓦茶业有限责任公司 Include the instant drink type beverage composition for treating dental erosion of the stabilization of lipophilic active agent
US11331268B2 (en) 2016-11-18 2022-05-17 The University Of Western Australia Taste masking product
JP7182639B2 (en) * 2018-03-01 2022-12-02 エルテーエス ローマン テラピー－ジステーメ アーゲー Oral dosage form containing theobromine-free cocoa
CN109053718B (en) * 2018-08-09 2022-06-03 天津理工大学 A kind of rosiglitazone saccharin salt and preparation method thereof
CN111729087A (en) * 2020-07-24 2020-10-02 成都大学 Lipid modification of a selective β2 receptor agonist and preparation method and use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB785574A (en) * 1955-03-29 1957-10-30 Pfizer & Co C Pharmaceutical compositions containing tetracycline antibiotics
GB918955A (en) * 1960-05-19 1963-02-20 Thomae Gmbh Dr K Pharmaceutical laxative compositions comprising 4,4-dihydroxy-2-amino triphenylmethane
FR2717387B1 (en) * 1994-03-17 1996-10-18 Hi Pharmtech Process for the production of chewable tablets based on troxerutin, calcium carbonate, calcium phosphate, arginine aspartate, amoxicillin arginine glutamate.
SE9803986D0 (en) * 1998-11-23 1998-11-23 Pharmacia & Upjohn Ab New compositions
JP2001106641A (en) * 1999-10-06 2001-04-17 Tendou Seiyaku Kk Intraoral medicine
JP2001114668A (en) * 1999-10-13 2001-04-24 Meiji Seika Kaisha Ltd Chocolate preparation
JP2002193839A (en) * 2000-12-27 2002-07-10 Meiji Seika Kaisha Ltd Cocoa pharmaceutical preparation
US20020172732A1 (en) * 2001-03-21 2002-11-21 Wies Ter Laak Composition comprising cocoa
SE0103211D0 (en) * 2001-09-27 2001-09-27 Pharmacia Ab New formulations and use thereof

Also Published As

Publication number Publication date
CL2004000564A1 (en) 2005-02-04
AR043772A1 (en) 2005-08-10
CA2519155A1 (en) 2004-10-07
JP2006521348A (en) 2006-09-21
BRPI0408655A (en) 2006-03-28
CN1764440A (en) 2006-04-26
EP1605921A1 (en) 2005-12-21
WO2004084865A1 (en) 2004-10-07
AU2004224557B2 (en) 2009-06-18
JP2011079841A (en) 2011-04-21
AU2004224557A1 (en) 2004-10-07
TW200503782A (en) 2005-02-01
ZA200507719B (en) 2007-09-26
MXPA05010196A (en) 2005-11-08

Similar Documents

Publication Publication Date Title
SE0300831D0 (en) New formulations and use therof
WO2004112711A3 (en) Oral extended-release composition
NO993520L (en) Dosage forms and methods for better erectile dysfunction
DE60331236D1 (en) ORAL COMPOSITIONS FOR THE TREATMENT OF DIABETES
HUP0301349A2 (en) Formulations for il-11
MY143795A (en) Tetrahydropyridoindole derivatives
HUP0301416A2 (en) Improved thyroid hormone formulations
ECSP045029A (en) VALDECOXIB COMPOSITIONS OF INTRAORAL DISGREGATION
BG108516A (en) Pharmaceutical formulation
IL154731A0 (en) Ion-strength independent sustained release pharmaceutical formulation
SE9700885D0 (en) New pharmaceutical formulation
NO331082B1 (en) Formulation of kahalalide F, comprising such a formulation, as well as reconstituted solution thereof and use of a diluted reconstituted solution for the manufacture of a medicament for the treatment of cancer
ATE262893T1 (en) DOSAGE FORMS FOR THE TREATMENT OF ORAL MYCOSES
RS50148B (en) Use of docetaxel for treating hepatocellular carcinoma
DE60202590D1 (en) 2H-1-BENZOPYRANE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS
TW200507838A (en) Active substance combination comprising a 2,5-dihydroxybenzenesulfonic compound and a potassium ion channel modulator
DE60311665D1 (en) PHARMACEUTICAL COMPOSITIONS
SE0001916D0 (en) Novel formulation
HK1065305A1 (en) Substituted 4-aminocyclohexanol derivatives
DK1273301T3 (en) Pharmaceuticals based on active ingredients that can be used for illicit administration
EP1603595A4 (en) Pharmaceutical composition for treatment of drug dependence
SE0103210D0 (en) New formulations and use thereof
WO2004052331A3 (en) Use of a cotton honeydew extract as active ingredient in or for preparing a cosmetic and/or pharmaceutical composition
SE0300830D0 (en) New formulations and use thereof
AU2003285125A8 (en) Polymer compositions comprising antifibrotic agents, and methods of treatment, pharmaceutical compositions, and methods of preparation therefor